GORC is the study administrative sponsor and the clinical trial, known as the LION Study, will be conducted in collaboration with clinician scientists at the
“The biodistribution study is a logical step in the clinical development of laquinimod eye drops with the aim to bring a well-tolerated treatment option to patients with a serious disease. Patients with non-anterior non-infectious uveitis (NA-NIU) require high doses of immunosuppressive treatments and there is an urgent need for novel therapies which could reduce the need for systemic corticosteroids. We are very pleased to start the collaboration with renowned and experienced organizations such as
The biodistribution study aims to evaluate whether laquinimod reaches the posterior chamber of the eye to support further development in patients with NA-NIU. The study is supported by preclinical data from rabbits where laquinimod was shown to distribute into the posterior segment of the eye following daily instillations of laquinimod eye drops. Furthermore, the completed phase I clinical study in healthy subjects showed no safety or tolerability concerns with daily instillations up to 21 days.
GORC, established in 2017 is a not-for-profit organization that assists clinicians, scientists and researchers to advance diagnosis and therapy for ophthalmic diseases. Professor and Principal Investigator
© Modular Finance, source